Know Cancer

or
forgot password

A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression


Phase 1
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression


To determine the safety, tolerability, and maximum tolerated dose (MTD) of MEDI 547 in a
dose escalation cohort for either administration schedule 1 dose every 3 weeks or 1 dose
every week in adult subjects with relapsed or refractory solid tumors.


Inclusion Criteria:



- For the dose-escalation cohort: cancer relapsed or refractory to at least 1 prior
standard care systemic regimen standard therapy with previous histological
confirmation of diagnosis of fallopian tube, primary peritoneal, endometrial,
cervical, prostate, non-small cell lung, esophageal, gastric, bladder, and renal cell
carcinomas or melanoma. Subjects with relapsed or refractory breast, epithelial
ovarian, or colon cancer with previous histological confirmation of diagnosis must
have progressed through more than 1 prior regimen of therapy. For patients enrolling
at the NCI, pathology must be confirmed by the Department of Pathology, CCR, NCI.

- For the dose-expansion cohort: relapsed or refractory epithelial ovarian cancer with
progression through more than 1 prior regimen of therapy, or relapsed or refractory
fallopian tube, or primary peritoneal cancer with progression after at least 1 prior
standard care systemic regimen, with previous histological confirmation of cancer
diagnosis. For patients enrolling at the NCI, pathology must be confirmed by the
Department of Pathology, Center for Cancer Research (CCR), NCI.

- Patients with the following histologic epithelial ovarian cancer cell types are
eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous
adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed
epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or
adenocarcinoma not otherwise specified (NOS).

- For the dose-expansion cohort of subjects with relapsed or refractory ovarian cancer,
subjects must have an archival tumor sample that demonstrates EphA2 expression by
immunohistochemical stain.

- Males or females at least 18 years of age at the time of obtaining informed consent.

- Women of childbearing potential must have a negative serum pregnancy test within 72
hours prior to MEDI-547 administration; and men and women of reproductive potential
must agree to practice an effective method of avoiding pregnancy (this is not to
include oral or implanted contraceptives (such as the "pill", the "patch", a Depo
Provera shot, or hormone laced intrauterine device, but allows the following: non
hormonal (copper), intrauterine device, female condom, diaphragm with spermicide,
cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual
partner) beginning at the time the ICF is signed, and must agree to continue using
such precautions while receiving MEDI-547 through 30 days after the last dose of
MEDI-547.

- For the dose-escalation cohort: measurable disease by Response Evaluation Criteria in
Solid Tumors (RECIST) criteria is desirable but not required. The following are not
considered measurable: pleural effusion or ascites; osteoblastic/osteoclastic
lesions or evidence of disease on bone scan alone; progressive irradiated lesions
alone, bone marrow involvement, brain metastases, malignant hepatomegaly by physical
exam alone; or chemical markers (eg, CA-125, carcinoembryonic antigen [CEA], or
prostate specific antigen [PSA]). Recurrent disease following surgery or
radiotherapy is measurable provided that 30 days have elapsed since treatment and
that measurable disease exists outside the radiation port, or there is clear
progression within the radiation port.

- For the dose-expansion cohort: measurable disease, by RECIST criteria is required.
The following are not considered measurable: pleural effusion or ascites;
osteoblastic/osteoclastic lesions or evidence of disease on bone scan alone;
progressive irradiated lesions alone, bone marrow involvement, brain metastases,
malignant hepatomegaly by physical exam alone; or chemical markers (eg, CA-125, CEA,
or PSA). Recurrent disease following surgery or radiotherapy is measurable provided
that 30 days has elapsed since treatment and that measurable disease exists outside
the radiation port, or there is clear progression within the radiation port.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

- Life expectancy of greater than 16 weeks.

- For subjects who had prior treatment with chemotherapy, biological therapy,
radiotherapy, or investigational therapy or had prior surgery: eligible for study
entry if at least 30 days have passed since their treatment/surgery, provided that
all toxicities related to prior treatment have resolved to ≤ Grade 1 severity by
National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0
(NCI CTCAE v3.0 and all surgical wounds have healed.

- Prior immunotherapy with approved agents (eg, trastuzumab, cetuximab, panitumumab,
bevacizumab) is allowable if at least 30 days have passed.

- Absolute neutrophil count (ANC) ³ 1500/mm3, platelets ³ 100,000/mm3, hemoglobin >
10.0 g/dL, serum creatinine greater than or equal to 1.5 times the upper limit of
normal [ULN] or calculated creatinine clearance > 50 mL/min, serum bilirubin greater
than or equal to 2 times the ULN, alkaline phosphatase < 3 times the ULN, and
aspartate transferase (AST) and alanine transferase (ALT) greater than or equal to 3
times the ULN.

- Prothrombin time (PT), partial thromboplastin time (PTT), and international
normalized ratio (INR) that are within normal institutional limits.

- Written informed consent and Health Insurance Portability and Accountability Act
(HIPAA) authorization (applies to covered entities in the USA only) obtained from the
subject prior to receipt of any study medication or beginning study procedures.

Exclusion Criteria:

- Pregnant or lactating women.

- A history of central nervous system metastases or primary central nervous system
tumors.

- Symptomatic pleural effusion or ascites requiring paracentesis.

- Symptomatic peripheral neuropathy of Grade 2 or greater.

- Respiratory insufficiency requiring oxygen treatment, or lymphangitic involvement of
lungs.

- Any evidence of hematemesis, melena, hematochezia, grade 2 or higher hemoptysis, or
gross hematuria. Patients with grade 1 hemoptysis or microscopic hematuria will be
permitted on study.

- Active or recent history (within 3 months) of keratitis or conjunctivitis.

- A history of significant adverse events related to a previously administered
monoclonal antibody.

- A history of human immunodeficiency virus (HIV) or hepatitis virus infection
(HBV,HCV)will be excluded to eliminate the risk of increased adverse events due to
immune compromise or liver dysfunction.

- Any evidence or history of myocardial infarction, angina, or arrhythmia (including
atrial fibrillation, multifocal premature ventricular contractions, ventricular
bigeminy or trigeminy, ventricular tachycardia or requirement for anti-arrhythmics
including digoxin), within 6 months prior to initiation of study drug.

- Any evidence of uncontrolled hypertension (systolic blood pressure > 150 mm Hg)
within 3 months prior to initiation of investigational product.

- Subjects currently on anticoagulant therapy for thromboembolic disorders or
prophylactic reasons will be excluded.

- Any evidence of severe congestive heart failure with severity New York Heart
Association classification > Class 1 within the past 12 weeks.

- A marked baseline prolongation of QTc interval (eg, demonstration of QTc interval ≥
500 millisecs [ms]).

- A prior stroke or transient ischemic attack (TIA) within 6 months prior to initiation
of (investigational product) MEDI-547.

- Any evidence of an active infection or systemic use of antimicrobials within 72 hours
prior to initial treatment with MEDI-547.

- Current or planned participation (from the day of study entry through 30 days after
the last dose of study drug) in a research protocol in which another investigational
agent or therapy may be administered.

- Received another investigational agent within 30 days prior to initiation of study
drug or not fully recovered from prior investigational treatment.

- A requirement for palliative chemotherapy, hormonal therapy, radiotherapy, surgery,
or immunotherapy during the course of the study.

- For subjects in the dose-expansion cohort, history of prior malignancies within the
past 5 years other than non-melanomatous skin cancers that have been controlled,
carcinoma in situ of the cervix, or superficial bladder cancer.

- A general medical or psychological condition or behavior, including substance
dependence or abuse that, in the opinion of the investigator, might not permit the
subject to complete the study or sign the informed consent.

- Any condition that in the opinion of the investigator would interfere with evaluation
of the investigational product or interpretation of study results.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerability of MEDI-547 will be assessed based on the incidence of AEs, SAEs, laboratory abnormalities, physical examination changes, toxicities leading to permanent discontinuation of MEDI-547 and MEDI-547-related deaths.

Outcome Time Frame:

30 days after the last dose of MEDI-547.

Safety Issue:

Yes

Principal Investigator

Sherry Warwick

Investigator Role:

Study Director

Investigator Affiliation:

MedImmune LLC

Authority:

United States: Food and Drug Administration

Study ID:

MI-CP177

NCT ID:

NCT00796055

Start Date:

August 2009

Completion Date:

June 2010

Related Keywords:

  • Cancer

Name

Location

Research SiteBaltimore, Maryland  
Research SiteBattle Kreek, Michigan